A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent

NCT02046603 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

162

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Tocilizumab
DRUG: DMARDs
DRUG: Oral Corticosteroids
DRUG: Methotrexate

Sponsor

Hoffmann-La Roche